Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Tarih
2018
Yazar
Spencer, Mike
Dimopoulos, Meletios A.
Robinson, Don
Potamianou, Anna
van de Velde, Helgi
Sargin, Deniz
Terpos, Evangelos
Katodritou, Eirini
de la Rubia, Javier
Hungria, Vania
Hulin, Cyrille
Roussou, Maria
Delforge, Michel
Bries, Greet
Stoppa, Anne-Marie
Aagesen, Jesper
Belch, Andrew
Ahlberg, Lucia
Diels, Joris
Olie, Robert A.
Üst veri
Tüm öğe kaydını göster
Özet
Objective: The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE (R) OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice.
Bağlantı
http://hdl.handle.net/20.500.12627/146016
https://doi.org/10.1111/ejh.13147
Koleksiyonlar